Arix Bioscience
plc
Change of
Broker
LONDON, 07 November, 2019: Arix Bioscience plc
(“Arix”, LSE: ARIX) a global venture capital company focused on
investing in and building breakthrough biotech companies, today
announces that it has appointed Peel Hunt LLP as joint corporate
broker, with immediate effect, alongside its existing corporate
broker Jefferies International Limited.
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 714 1787
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com